HVHalena R. VanDeusen

Halena R. VanDeusen

*This is an algorithmically generated author record based on publicly available information.

Halena R. VanDeusen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative.Implications:Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.

  • Open Access

    Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    Supplemental Table 1: Known genetic mutations of genes commonly mutated in mCRPC in cell lines used in phosphoproteome analysis Supplemental Table 2: Phospho-Serine/Threonine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 3: Phospho-Tyrosine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 4: Kinase Substrate Enrichment Analysis results from phospho-serine/threonine proteome dataset Supplemental Table 5: Kinase Substrate Enrichment Analysis results from phospho-tyrosine proteome dataset Supplemental Table 6: Phospho-Serine/Threonine proteome of Adenocarcinoma or Small cell/Mixed phenotype mCRPC patient samples Supplemental Table 7. Spearman's Correlation Between the Dependency Ranks of RET and Other Genes in Prostate Cancer Cell Lines Supplemental Table 8. RET Dependency Scores of Cancer Cell Lines

  • Open Access

    Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.

  • Open Access

    Data from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative.Implications:Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.

  • Open Access

    Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.

  • Open Access

    Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    Supplemental Table 1: Known genetic mutations of genes commonly mutated in mCRPC in cell lines used in phosphoproteome analysis Supplemental Table 2: Phospho-Serine/Threonine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 3: Phospho-Tyrosine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 4: Kinase Substrate Enrichment Analysis results from phospho-serine/threonine proteome dataset Supplemental Table 5: Kinase Substrate Enrichment Analysis results from phospho-tyrosine proteome dataset Supplemental Table 6: Phospho-Serine/Threonine proteome of Adenocarcinoma or Small cell/Mixed phenotype mCRPC patient samples Supplemental Table 7. Spearman's Correlation Between the Dependency Ranks of RET and Other Genes in Prostate Cancer Cell Lines Supplemental Table 8. RET Dependency Scores of Cancer Cell Lines

  • Open Access

    Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative. Implications: Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.